Mario Negri Institute for Pharmacological Research
PharmaMilan, Italy, Italy · Est. 1963
Mario Negri Institute for Pharmacological Research is an independent, non-profit research organization focused on drug discovery and development in therapeutic areas including oncology, cardiovascular disease, and neurology.
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
4
Indications↗
Distinct diseases across all programs
92
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 31
Phase 21
Preclinical1
By Therapeutic Area
top 2
Neurology
125%
Musculoskeletal
125%
R&D Momentum
55/100
Pipeline Velocity
22/100
Trial Completion Rate
68/100
Pipeline Concentration
38/100
Pipeline Freshness
72/100
Strategic Signals
- ↗Active in Neurology but thin pipeline — potential licensing opportunity
Activity
Key Events
Aug 12, 2026TrialImplementation of New Models of Ovarian Carcinoma Resistant to Therapy
Aug 12, 2026TrialObinutuzumab for Primary Membranous Nephropathy: a Pilot Study in Patients With Rituximab-resistant or Rituximab-dependent Nephrotic Syndrome and in Patients Intolerant to Rituximab (the ORION Study)
Jul 16, 2026TrialDevelopment and Validation of a Natural Language Processing Tool to Enable Clinical Research in Emergency and Acute Care Medicine: Retrospective Cohort Study
Jul 14, 2026TrialRescue Therapy With the Human Anti-CD38 Antibody MOR202 (Felzartamab) in Patients With Membranous Nephropathy Who Failed Anti-CD20 Target Therapy
Jul 7, 2026TrialStudy of Pathological and Regenerative Molecular and Cellular Processes Triggered After Traumatic Brain Injury: Analysis of Biopsy Specimens
Jun 26, 2026TrialA Phase IV Trial to Confirm the Efficacy of Olaparib in Combination With Bevacizumab as Frontline Treatment of HRD Positive Ovarian Tumors
Jun 24, 2026TrialDeciphering the Role of Thyroid Hormones in Severe Non-ADPKD Chronic Kidney Disease
Apr 30, 2026TrialPragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib
3 more events
Feb 1, 2026TrialObinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
Aug 7, 2025TrialPhase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen
Jul 8, 2025TrialPatiromer and Diet/hrQoL in Chronic Dialysis
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyCardiovascularNeurology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Musculoskeletal
Unknown / Other
Musculoskeletal
Osteoarthritis
Acetyl-L-carnitinePreclinical
Neurology
Ataxia
Acetyl-L-carnitinePreclinical
Encephalopathy
Acetyl-L-carnitinePreclinical
Unknown / Other
Trial
Acetyl-L-carnitinePhase 3
Noble gas ArgonPhase 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)